NDA 214461 · Emergent Biodefense
Tembexa
Brincidofovir · Oral
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Aug 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 4, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
6 Phase 3, 2 recruiting
FAERS reports
139
114 serious, 57 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED RISK FOR MORTALITY WHEN USED FOR LONGER DURATION An increased incidence of mortality was seen in TEMBEXA-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED RISK FOR MORTALITY WHEN USED FOR LONGER DURATION See full prescribing information for complete boxed warning. An increased incidence of mortality was seen in TEMBEXA- treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease [see Warnings and Precautions ( 5.1 )].
What it is approved for
From the label in effect Jul 1, 2025.
TEMBEXA is an orthopoxvirus nucleotide analog DNA polymerase inhibitor and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. ( 1.1 ) Limitations of Use: • TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. ( 1.2 ) • The effectiveness of TEMBEXA for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( 1.2 ) • TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals. ( 1.2 ) 1.1 Treatment of Human Smallpox Disease TEMBEXA ® is indicated for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates. 1.2 Limitations of Use TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease [see Warnings and Precautions ( 5.1 , 5.2 )] . The effectiveness of TEMBEXA for the treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical [see Clinical Studies ( 14 )] . TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals.
Mechanism: Brincidofovir is an antiviral drug against variola (smallpox) virus [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 4, 2021 Original approval · Type 2 - New Active Ingredient · priority review OrphanLetterLabelReview
1 products under this application
- TEMBEXA · BRINCIDOFOVIR 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brincidofovir" as an intervention, any sponsor and status, largest first.
- A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT RecipientsPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT01769170 · 452 participants · Start Aug 2013 · Primary completion Dec 2015
Drug: Brincidofovir · For: CMV
Sites: La Jolla, California; Los Angeles, California; Denver, Colorado · 43 sites in all
- Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant RecipientsPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00942305 · 239 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Brincidofovir; Placebo · For: Cytomegalovirus Infection
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 26 sites in all
- Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA VirusesPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT01143181 · 210 participants · Start Dec 2010 · Primary completion Dec 2012
Drug: Brincidofovir · For: Double-stranded DNA Virus
Sites: Loma Linda, California; Los Angeles, California; Orange, California · 37 sites in all
- Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus InfectionPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02087306 · 201 participants · Start Mar 2014 · Primary completion Jun 2016
Drug: Brincidofovir · For: Adenovirus Infection
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 33 sites in all
- A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCTPivotal-lookingRecruiting
SymBio PharmaceuticalsIndustry
NCT07387367 · 180 participants (planned) · Start Mar 17, 2026 · Primary completion Jan 31, 2028
Drug: cidofovir; Brincidofovir · For: Adenovirus Infections
Sites: Phoenix, Arizona; Duarte, California; Palo Alto, California · 81 sites in all
SymBio PharmaceuticalsIndustry
NCT04706923 · 53 participants · Start Aug 16, 2021 · Primary completion May 15, 2025
Drug: BCV · For: Adenovirus Infections; Cytomegalovirus Infection
Sites: Los Angeles, California; San Francisco, California; Chicago, Illinois · 11 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT01241344 · 52 participants · Start Nov 2010 · Primary completion Jun 2013
Drug: Brincidofovir · For: Adenovirus Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 30 sites in all
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompleted
Emergent BioSolutionsIndustry
NCT05935917 · 44 participants · Start May 30, 2023 · Primary completion Aug 14, 2023
Drug: Brincidofovir · For: Smallpox
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use40
- acute kidney injury27
- adenovirus infection15
- drug ineffective14
- drug resistance12
- graft versus host disease in gastrointestinal tract11
- hypotension11
- immune reconstitution inflammatory syndrome11
- multiple organ dysfunction syndrome11
- condition aggravated9
- cytomegalovirus infection9
- pancytopenia9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 17 |
| 2017 | 12 |
| 2018 | 9 |
| 2019 | 23 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 19 |
| 2024 | 22 |
| 2025 | 11 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adenovirus diseases: a systematic review and meta-analysis of 228 case reports.
Gu J, Su QQ, Zuo TT, et al. · Infection 2021 · Meta-Analysis, Systematic Review
- Therapeutics for treating mpox in humans.
Fox T, Gould S, Princy N, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
Chen K, Cheng MP, Hammond SP, et al. · Blood Adv 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant.
Hiwarkar P, Amrolia P, Sivaprakasam P, et al. · Blood 2017 · Clinical Trial, Multicenter Study
- Prevention and Treatment of Monkeypox: A Systematic Review of Preclinical Studies.
Sudarmaji N, Kifli N, Hermansyah A, et al. · Viruses 2022 · Systematic Review
- Managing Monkeypox Virus: Characterizing Common Cutaneous Manifestations and Antiviral Efficacy.
Khan M, Rahman S, Ahmed F, et al. · J Drugs Dermatol 2023 · Systematic Review
Sponsor: Emergent Biodefense
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.